Mobile

An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therap...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-006913-34

An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate safety and tolerability during long-term treatment with degarelix one-month dosing regimen in prostate cancer patients

Critère d'inclusion

  • Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated

Liens